Newsletter summary

The scale of operation has been steadily improved. Heavy Pharmaceutical Holdings has achieved revenue of more than 80 billion yuan in 2023.TopfreenftgamesplaytoearnOn the evening of April 26th, heavy Pharmaceutical Holdings (000950) disclosed its annual performance report. In 2023, the company focused on its main business, consolidated the advantages of the four traditional business formats, and cultivated new momentum for the development of five major market segments.Topfreenftgamesplaytoearn...

Text of news flash

Steady increase in business scale heavy Pharmaceutical Holdings achieved revenue of more than 80 billion yuan in 2023. On the evening of April 26th, heavy Pharmaceutical Holdings (000950) disclosed its annual performance report. In 2023, the company focused on the main business and consolidated the advantages of the four traditional business forms. cultivate new momentum for the development of five major market segments, persist in making progress in the midst of stability, and achieve operating income of 80.119 billion yuan, an increase of 18.12% over the same period last year; and return to the mother's net profit of 655 million yuan. The total profit is 1.009 billion yuan, and the basic earnings per share is 0.38 yuan. It is proposed to pay a cash dividend of 0.50 yuan (including tax) for every 10 shares. During the reporting period, the company completed nearly 20 equity investment projects through new or external mergers and acquisitions, bringing incremental sales of nearly 2.5 billion yuan, filling in many blank market layouts in Heilongjiang, Hebei, Guangxi and other blank markets and continuously thickening the network layout. now it has achieved the layout in 32 provinces, autonomous regions, municipalities directly under the Central Government and special administrative regions, covering 137 prefecture-level cities, and gradually achieving the goal of layout in more than 300 prefecture-level cities across the country. In 2023, the company ranked fifth in China's pharmaceutical wholesale enterprises, and the ranking of China's top 500 enterprises jumped to 340. at the same time, the company continued to invest in digital construction, empowered the business through digital systems, and built its own pharmaceutical e-commerce "heavy pharmaceutical cloud business" platform. build an online operation team to optimize self-supporting B2B platform services with a 24-hour one-stop e-commerce procurement model Since the C-end platform was built to open up online platforms such as Peace to Home and online drug search, during the reporting period, the transaction volume of the online platform of "heavy Pharmaceutical Cloud Merchants" exceeded 1.5 billion yuan, an increase of 52% over the same period last year. In addition, the company continues to invest in medical research and development, mainly to high-end generic drugs, the development of characteristic varieties of traditional Chinese medicine. During the reporting period, there are more than 10 projects under research, involving cardio-cerebrovascular, mental nerves, digestion and metabolism, autoimmunity and other R & D pipelines, the first MAH variety olmesartan axetil tablets was approved and completed commercial sales, 1 project completed CDE registration review, 1 project completed the submission of CDE supplementary research materials, other varieties under research are in different stages of pharmacy, clinic and waiting to be declared, and the echelon of projects under study has been formed. Heavy Pharmaceutical Holdings said that under the strategic guidance of "1200 double three hundred cities, Sanhua four Energy and five Route Army", the company has successively set up the equipment Strategy Division, the Retail Strategy Division, the traditional Chinese Medicine Strategy Division, the E-commerce Strategy Division, the New Business Strategy Division and the Marketing Center, so as to strengthen the organizational strength and overall planning of each sub-industry development strategy, and at the same time through matrix management. Gradually deepen the excavation of various segments of the field, increase market share, improve profit margins, and lay a solid foundation for achieving high-quality development goals. (Zheng Yuchuan) proofread: Zhu Tianting